The KTN1 Knockout Jurkat Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T-lymphocyte cell line, engineered to disrupt the human KTN1 gene. This polyclonal pool provides a loss-of-function model for investigating the cellular roles of kinectin (KTN1), a key adaptor in microtubule-dependent vesicle transport. The use of CRISPR/Cas9 technology ensures efficient gene disruption across a heterogeneous cell population, enabling robust functional studies without the need for single-cell cloning.
The Jurkat cell line, originally established from the peripheral blood of a 14-year-old male with acute T-cell leukemia, is a widely employed model for T-cell receptor (TCR) signaling, immune synapse formation, and T-cell leukemia biology. Jurkat cells exhibit high transfection efficiency and are amenable to CRISPR/Cas9-based genome editing, making them an ideal host for knockout studies. Their well-characterized signaling pathways and rapid proliferation support scalable experimental designs for both basic and translational research.
The KTN1 gene encodes kinectin, a membrane receptor that specifically binds the heavy chain of kinesin-1 (KIF5B) and kinesin light chain (KLC), anchoring motor complexes to cargo vesicles and organelles such as the endoplasmic reticulum (ER). This interaction is essential for microtubule-based, minus-end-directed intracellular transport, influencing ER morphology, organelle distribution, and cell migration. Upstream regulators, including EGF signaling, integrin activation, and Rho GTPases, modulate KTN1 activity in response to cellular cues. Downstream, KTN1 governs KIF5 motor activity, focal adhesion turnover, and membrane trafficking. The pathway is integrated with dynein, Rab GTPases, and various vesicle cargo adaptors, positioning KTN1 as a central coordinator of cytoskeletal dynamics and vesicle trafficking.
In Jurkat T-cells, KTN1-mediated transport is critically linked to processes that drive leukemia pathophysiology. Disruption of KTN1 can impair ER distribution, which is necessary for proper immune synapse formation and TCR signal transduction. Additionally, KTN1 plays a role in cell migration and invasion??hallmarks of leukemic dissemination??making this knockout model highly relevant for studying mechanisms of T-cell leukemia aggressiveness. By ablating KTN1 function, researchers can dissect its contribution to adhesion, migration, and cytoskeletal reorganization under conditions mimicking the tumor microenvironment.
This polyclonal knockout cell model is suited for a broad range of experimental applications. Researchers may perform Western blotting to confirm loss of KTN1 protein expression, immunofluorescence to visualize altered ER morphology, and live-cell imaging to assess defects in vesicle transport. Quantitative assays such as wound healing and flow cytometry for adhesion markers can evaluate migratory and adhesive phenotypes. Co-immunoprecipitation can verify disrupted KTN1-KIF5B binding, while microtubule co-sedimentation assays probe motor-cargo coupling. Drug response studies using microtubule-targeting agents are also feasible, offering insights into therapeutic sensitivities. For additional information or technical support regarding this product, contact Ascent Research.
